Haruo Usuda - Gynecology

Author Information

Haruo Usuda is affiliated with the Division of Obstetrics and Gynecology at The University of Western Australia in Crawley, Western Australia, Australia, and the Center for Perinatal and Neonatal Medicine at Tohoku University Hospital in Sendai, Miyagi, Japan. His work primarily focuses on perinatal care and the treatment of extremely preterm infants, with significant contributions to the development of artificial placenta-based life support systems.

Research Contributions

Haruo Usuda has made significant contributions to the field of obstetrics and gynecology, particularly in the care and treatment of extremely preterm infants. His recent research includes studies on perinatal care, antenatal steroid therapy, and the use of artificial placenta-based life support systems. His work has explored various aspects of fetal medicine, including lung maturation, intrauterine inflammation, and the efficacy of synthetic red cell therapy. These contributions have important implications for improving outcomes for preterm infants.

Aliases

H Usuda, Haruo Usuda

Publication and Citation Metrics

Metric	Value
Citation Count	495
h-index	12
Paper Count	58

Publications:

Perinatal Care for the Extremely Preterm Infant

DOI: 10.1016/j.siny.2022.101334

Year: 2022

1% of the clinical dose used for antenatal steroid therapy is sufficient to induce lung maturation when administered directly to the preterm ovine fetus.

DOI: 10.1152/ajplung.00058.2022

Year: 2022

Continuous but not pulsed low-dose fetal betamethasone exposures extend the durability of antenatal steroid therapy.

DOI: 10.1152/ajplung.00018.2022

Year: 2022

Direct administration of the non-competitive interleukin-1 receptor antagonist rytvela transiently reduced intrauterine inflammation in an extremely preterm sheep model of chorioamnionitis

DOI: 10.1371/journal.pone.0257847

Year: 2021

Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birth weights when administered to pregnant sheep in combination with betamethasone acetate.

DOI: 10.1016/j.ajog.2021.10.001

Year: 2021

Assessment of synthetic red cell therapy for extremely preterm ovine fetuses maintained on an artificial placenta life-support platform.

DOI: 10.1111/aor.14155

Year: 2021

Sequential Exposure to Antenatal Microbial Triggers Attenuates Alveolar Growth and Pulmonary Vascular Development and Impacts Pulmonary Epithelial Stem/Progenitor Cells

DOI: 10.3389/fmed.2021.614239

Year: 2021

THE ARTIFICIAL PLACENTA: SCI-FI OR REALITY?

DOI: 10.1016/j.rmclc.2021.10.005

Year: 2021

Successful use of an artificial placenta-based life support system to treat extremely preterm ovine fetuses compromised by intrauterine inflammation.

DOI: 10.1016/j.ajog.2020.04.036

Year: 2020

Organ blood flow in response to infusion of arginine vasopressin in premature fetal sheep

DOI: 10.1111/ped.14141

Year: 2020

What Role Does Insurance Play?

What Causes Simple Virilizing?

What is the Bishop Score?

How Can Patients Advocate for Their Mental Health?

What Can Patients Expect During the Procedure?

Who is a Candidate?

What Happens if GDM is Diagnosed?

How does ovarian dysgenesis affect fertility?

What are Common Reproductive Issues?

How Can Hormonal Imbalances be Prevented?

Partnered Content Networks

Relevant Topics